Presentation of results for third quarter 2013
DiaGenic will present results for third quarter 2013 on Wednesday 13 November 2013. Interim report and presentation slides will be posted on www.newsweb.no and on DiaGenic’s web page: www.diagenic.com on 13 November at approximately 08:00 CET.
A conference call for presentation of the results is scheduled the same day at 09:00 CET.
A presentation will be held at 11:00 CET at DiaGenics premises, Grenseveien 92, 0663 Oslo.
Please use the dial-in details listed below, corresponding to your location, to participate in the conference call at 09:00 CET. The conference ID is: 1920062
Participant Access - Dial in 5-10 minutes prior to the start time using the number / Confirmation Code below...
| Confirmation Code: | 1920062 |
| Participants, Local - Oslo, Norway: | +47 2316 2771 | |||
| Participants, Local - Stockholm, Sweden: | +46 (0)8 5033 6538 | |||
| Participants, Local - Copenhagen, Denmark: | +45 32 71 16 59 | |||
| Participants, Local - New York, United States of America: | +1 212 444 0481 | |||
| Participants, Local - London, United Kingdom: | +44(0)20 3427 1918 | |||
| Adobe Connect Web Meeting: | ||||
| To be entered directly into your Adobe Connect Event click on the Direct Access Link: http://webmeeting.adobeconnect.com/e1920062 Need Help? Contact Customer Support: Phone: +353 (0) 23 88 32131 E-Mail: EUCSTechsupport@pgi.com |
||||
The conference call will be available in re-play after the presentation on DiaGenic’s webpage www.diagenic.com
Contact:
Paul de Potocki, Chief Executive Officer
Telephone: 47 2324 8950
e-mail: paul.depotocki@diagenic.com
Ruben Ekbråten, Chief Financial Officer
Telephone: 47 2324 8950
e-mail: ruben.ekbraten@diagenic.com
About DiaGenic ASA
DiaGenic is an innovative Norwegian diagnostic company that seeks to create value for patients, partners and investors by developing innovative and patient friendly in vitro diagnostic (IVD) products for early detection of diseases. The company’s proprietary concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using a blood sample. DiaGenic is a world leader in identifying gene expression signatures in blood and is focused on the development of IVD biomarker products in the field of Alzheimer’s disease. The company protects its technology through an extensive patent portfolio. DiaGenic is listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com